Click cover above to view the Conference Guide

122 Pages·2013·8.51 MB·English

W
E
L
M C
O
M
E
U
R
O
F

S
R P
E
A
K
E
O R
S
T
13th Annual
S
E BIOTECH IN EUROPE
V
N INVESTOR FORUM
P
I R
E
S
E
N
T
E IN
30th September – 1st October 2013 G
C
O
P M
Hilton Zurich Airport Hotel, Switzerland
P
A
N
O IE
S
R
U Conference Guide
E

S
U
N P
P
O
R
T
I IN
G
O
R
G
H A
N
IS
A
C TIO
N
S
E
T
O
I OR
www.sachsforum.com G
A
B N
IS
E
R
S
t
b W
ack EL
:: n COM
e
x E
tu
Welcome
Sachs Associates are delighted to welcome you to the:
13th Annual
S
P
Biotech in Europe EA
K
E
R
S
Investor Forum
30th September-1st October 2013
Hilton Zurich Airport Hotel, Switzerland
Sachs Associates are delighted to welcome you to the 13th Annual Biotech in Europe Investor
Forum. Following the success of previous years, the forum once again provides access to an
exciting cross-section of venture-funded and small-cap companies with leading investors and
pharmas.
P
This Forum is highly transactional and is comprised of a series of panels and presentations R
E
S
from leading investment, pharmaceutical and biotech companies, each one providing an expert E
N
outlook on growth and investment activity in Europe’s Biotech industry. T
IN
G
The programme highlights the current issues surrounding the evolving M&A market, the Private C
Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, OM
this year’s programme features more than 80 company presentations from a range of publicly P
A
N
listed and private life science companies looking to raise finance and/or find partners. IE
S
General Information
The registration desk will be open from 8am on September 30th and from 8am on October 1st
although you are welcome to join the event at any time. Please collect a copy of the agenda for
information on timing and room allocation for each session.
S
Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to U
P
all participants. P
O
R
A Networking Lunch will be set up in the Zurich A & B rooms. T
IN
G
Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the O
event. R
G
A
N
IS
A
Request for Presentations T
IO
N
Please use the agenda to mark off presentations that you are interested in and email your request S
to [email protected] after the conference. We will endeavour to send you the requested
presentations as soon as we have been granted permission to do so by that specific presenter.
Please note that we DO NOT have copies of the slides that are shown during the conference.
O
R
G
A
N
IS
E
R
S
t
b W
ack EL
:: n COM
e
x E
tu
Events Diary
For regular updates, sponsorship, presenting and attending opportunities
and further information regarding any of our future events please contact
Sian Rodgers on [email protected]
S
P
E
A
MedTech & Diagnostics Innovations Summit K
E
R
21st November 2013 • Düsseldorf • Germany S
The Summit is being held to coincide with the leading annual international tradeshow Medica with
its 135,000 visitors and is designed to bring together a specialist audience from leading and growth
companies focused on M+A, alliances and Investment. The program will feature keynotes from
industry leaders and plenary panels on industry acquisitions; public markets, venture investment and
growth, company finance, and diagnostics. The subjects of regulation and reimbursement will also be
covered.
Apart from the plenary session the program will also feature 20+ public and private company
presentations focused on innovation and alliances/investment opportunities. The MedTech & Device
and Diagnostics presenting track will cover: Oncology, Cardiovascular, Imaging, Digital Healthcare,
Surgical Devices & Implants and Diagnostics. P
R
E
There will be many networking opportunities. There is a 1-to-1 online meeting system with meeting S
E
N
rooms provided. In addition, there will be networking breaks and a conference cocktail reception. T
IN
Participation will be limited and presentations by invitation. Financial Investors will receive G
C
complimentary passes. We plan an audience of 150 -200 delegates. O
M
P
A
N
7th Annual IE
S
European Life Science CEO Forum
For Partnering & Investing
4th – 5th March 2014 • Zurich • Switzerland
Back for its seventh year, this exclusive and highly transactional partnering event is a must
for companies wishing to meet with their peers, engage with leading investors and forge new
S
partnerships. U
P
P
Building on the success of this year’s event, the forum will provide an excellent platform to gain O
R
insight into partnering and investment trends in the Biotech and Pharma industry. Networking at the T
IN
Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. G
O
The conference will feature up to 80 presentations by large to mid size pharmaceutical companies R
G
looking for strategic alliances/partners. AN
IS
Do not miss out on this great opportunity to meet emerging companies, leading global investors and A
T
Big Pharma representatives! IO
N
S
14th Annual
Biotech in Europe Investor Forum
7th – 8th October 2014 • Zurich • Switzerland
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
Alain Huriez, Venture Partner, Advent Venture Partners & Chairman, EPEMED
Alain joined Advent in 2012 bringing 22 years of experience in management, drug development and financing in the life
sciences sector, including CEO of TcLand Expression and Neovacs, Associate Partner at Truffle Capital and Vice President t
at Quintiles. Alain is a medical doctor and holds an MBA and a Masters of Pharmaco-Economics from Paris La Sorbonne b S
University. Prior to joining the industry, he was head of the emergency room in a large teaching hospital and practiced as a ack PE
GAleanine rhaal sP rbaecetinti ornesepr ofonrs itbwleo fyoera srse.veral initiatives in Europe within the areas of personalized medicine, biomarkers and high :: nex AKER
value diagnostics through his work as chairman of EPEMED, the European Personalised Medicine Association he founded in tu S
2009. As an entrepreneur, he co-founded four French biotechnology companies.
Prof. Dr. André Rosenthal, CEO , Signature Diagnostics AG
André Rosenthal is founder and CEO of Signature Diagnostics AG, a cancer diagnostic company focused on prognostic and
predictive (companion diagnostic) biomarkers in colorectal cancer. The biomarker research of Signature is based on a large
prospective, multicenter clinical diagnostic study in colorectal cancer which has recruited more than 7.500 patients of all four
UICC stages. Fresh-frozen, FFPE tumour tissue specimens and plasma samples with longitudinal clinical annotation are used
for deep sequencing with the aim of developing accurate tumor tissue and plasma based tests.
André´s current interest is translational oncology with a focus on developing novel next generation sequencing (NGS) tests
P
based on circulating free DNA from plasma which can be used for monitoring colorectal cancer patients but also for early R
E
detection of colorectal cancer. In addition, we develop NGS tests for the prediction of outcome (prognosis) of colorectal S
E
cancer patients and for the prediction of response to treatment. Signature Diagnostics has developed a suite of five NGS tests N
T
in these indications. Our plasma test OncoDetect is an ultra deep sequencing test if circulating DNA and can be used for IN
monitoring patients with colorectal cancer of stage III and IV. This test was presented at the recent ASCO 2013 meeting. Our G
C
prognostic NGS test OncoSelect-III will be presented at the 17th ECCO meeting in September 2013 in Amsterdam. O
M
Between 1989-2003 André was a member of the core team involved in the world wide Human Genome Sequencing Project P
A
(HUGO), from 1989-93 in Cambridge (UK) with Sydney Brenner and John Sulston, from 1993 in Germany as a professor at N
the Friedrich Schiller University in Jena (Germany). He was in charge of the German Human Genome Sequencing Project and IE
S
led the chromosome 21 sequencing project in collaboration with Japanese researchers. His team in Jena also contributed
to the sequencing of human chromosome 8 and X. During 1989-2000 he participated in several positional cloning projects
of human disease genes including X-linked hydrocephalus, MASA syndrome and X-linked spastic, paraplegia (CRASH
syndrome), Turner syndrome, Nijmegen breakage syndrome, tricho-rhino-phalangeal syndrome type I, X-linked congenital
stationary night blindness, X-linked retinitis pigmentosa 2, MALT lymphoma, and others.
André has authored or co-authored 135 peer reviewed original papers. He is an inventor of many patents and patent
applications.
S
U
Anja König, Managing Director, Novartis Venture Fund PP
O
R
Anja is active in Switzerland and Europe and also responsible for expanding the fund’s presence to Asia Pacific. Prior to joining T
Novartis she was an Associate Partner at McKinsey and Company, a global consultancy, where she worked with companies IN
G
in health care in the US, Europe and Emerging Markets. Anja König is a scientist by training and holds a PhD in physics O
R
from Cornell University. Anja serves on the boards of Bicycle, Covagen, Heptares, F2G and Nabriva and works with Destiny, G
A
Neomics, Oxagen, PharmAbcine, Polyphor and Qurient Therapeutics. N
IS
A
T
IO
N
S
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
Bart Wuurman, CEO, Lanthio Pharma BV
Bart Wuurman, PharmD, has 25 years of International Pharma and Biotech Industry experience. He gained broad industry
experience, ranging from drug development, product licensing to General Management and fund raising with Organon, t
Medeva, Antisoma, DeNovo Pharmaceuticals and AM-Pharma. He was instrumental to raising around e40 million VC b S
financing and to closing licensing deals worth e700 million. Bart has been a biotech CEO for 11 years, in the UK and in the ack PE
Nine Uthtreerclahnt dasn. dB aLreti djoeinne.d Lanthio Pharma as CEO in 2011. He holds pharmaceutical sciences degrees from Dutch Universities :: nex AKER
tu S
Bernd Goergen, Senior Investment Manager, High-Tech Gründerfonds Management
Since 2008, Bernd Goergen, Ph.D. works for the High-Tech Gruenderfonds (HTGF) as Senior Investment Manager. The
biologist and DVFA-certified Biotech analyst combines 5 years of research experience in virology-immunology and in-depth
expertise from 7 years (1994-2000) international diagnostics marketing for global market leaders in Germany and the US.
Between 2000 and 2007 he joined the investment banking department of a major German bank, where he organised M&A
activities and capital market transactions like IPOs and capital increases for life science companies. Bernd currently manages
a portfolio of 14 companies for HTGF with a 50-50-split between medical devices and pharma/biotech. He also serves as a
board member in 4 of the funds life science firms.
P
R
Dr Bernd Muehlenweg, CBO, Nanobiotix ES
E
N
Bernd holds a doctorate in chemistry from the Technical University of Munich, extended by management training at the St. T
Gallen Business School, as well as several merger/acquisition and negotiation techniques seminars. He was responsible for IN
G
several negotiations and the execution of several licences and marketing contracts. Mr Muehlenweg is co-author of more C
O
than 17 publications and 2 patents. He is member of the Pharma Licensing Club of Germany. M
P
Before joining Nanobiotix Bernd was Business Development Director for Wilex AG in Munich, where he made significant A
N
contributions to position Wilex as a leader in the market of development of therapeutic molecules and diagnostic tools in IE
oncology. He joined Nanobiotix in 2011 where he is responsible for ensuring the sustainable growth of the Company by S
concluding strategic alliances with partners.
Beth Jacobs, Managing Partner, Excellentia Global Partners
Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, a global life sciences investment bank,
founded in 2008.
Beth has served in senior executive roles in her twenty five years of experience in both investment banking and in the
S
corporate sector. Prior to 2008, Beth was a partner at Bio-IB, a life sciences investment bank based in New York, as Managing U
P
Director and Co-Head of Global Capital Markets at ING Barings, shortly after their acquisition of Furman Selz LLC, where she P
O
founded and led its international institutional equity group for over 7 years. She started her career at Prudential Securities R
T
where she founded the international institutional equity business, and later headed the same product execution group at both IN
Morgan Stanley and Lehman Brothers. G
O
She currently serves on the Board of Directors of EF Foundation, a global educational services company based in Stockholm R
G
and Cambridge, Mass, Board of Governors of the New York Academy of Sciences, founding Global Ambassador for Susan G. A
N
Komen for the Cure, Board member for both the Harvard Kennedy School of Government Women’s Leadership Board and as IS
Vice Chairman of the Board for the Budapest Festival Orchestra. AT
IO
Beth received an MBA in international finance from American University in Washington, DC in conjunction with the School of N
S
Foreign Service, and a BA, cum laude, from Boston College. She also studied at Centre d’Etudes Internationale in Geneva,
Switzerland.
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
Carlos Buesa, CEO, Oryzon SA
Carlos is a specialist in the Biotech Industry. Dr Buesa got his PhD in Biochemistry and Molecular Biology from the University
of Barcelona, Spain in 1993. He was post-doctoral fellow in the Faculty of Medicine at the University of Ghent in Belgium and t
later Senior Investigator at the Flemish Institute of Biotechnology (VIB). b S
ac P
Back in Spain, in 2000, he founded Oryzon. Since inception he has served as Chief Executive Officer and Chairman of the k E
Bevooalrvde do ff rDoimre cat goresn. oUmnidcesr b haisse lde acdoemrsphainpy t htoe ac colminpicaanl yc ohmasp ganoty +w1it4h Mits e fiurrsots p irno gsreavmer ainl Efupnigdeinnge triocus nind sO anncodl othgey icno Pmhpaasney I /hIIaAs. :: nex AKER
tu S
He has taken the executive education programme (PADE) at the IESE Business School in Barcelona and several additional
educational programs in finances, negotiation skills, international commerce and advanced business development
He is now board member of the Spanish Association of BioIndustry (ASEBIO), VicePresident of the Association of Catalan
Biotechnology Companies (CataloniaBio), and he was also member of the Executive Committee of BioRegió de Catalunya, a
regional biocluster body that has been set up with the aim of improving of the biotechnology sector in Catalonia.
In addition, he sits on the board of other biotech companies like GEADIC Biotech, PaloBiofarma, Neurosciences technologies,
NINFAS Biotech and Oncnosis Pharma.
He is also board member in the VC-seed firms Inveready seed and Inveready Biotech.
Carole Nuechterlein, Head, F. Hoffmann-La Roche AG Roche Venture Fund
P
R
Carole Nuechterlein has headed the Roche Venture Fund since 2001. Prior to her current position, she worked in the E
S
pharmaceutical/biotech industry as an attorney for ten years. She joined Roche from SangStat in Fremont California where E
N
she was General Counsel. T
IN
Carole began her career working at Skadden Arps Slate Meagher & Flom in the M&A group. From there, she worked at G
C
Syntex/Roche in Palo Alto, California focusing on M&A, research collaborations and licensing deals. Due to her background in O
M
M&A, Carole led the negotiation team for the Roche acquisitions of GlycArt and Therapeutic Human Polyclonals.
P
A
She currently serves as a board observer at Aileron, Alios, Ambrx, BioFire Diagnostics and Epic. N
IE
She has a BA from Valparaiso University and a JD from University of Michigan. S
More information on the Roche Venture Fund can be found at www.venturefund.roche.com.
Chris Britten, Head of Business Development, Sanofi Pasteur-MSD
Chris is currently Head of Business Development at Sanofi Pasteur-MSD with responsibility for all business and corporate
development activities. Sanofi Pasteur-MSD is a Joint Venture between Sanofi Pasteur and Merck & Co. and is focused on
the development and commercialisation of vaccines in Europe. Chris is also the Managing Director of Vantage Life Sciences,
offering strategic and transaction advisory services to the life science sector. S
U
P
Chris joined Sanofi Pasteur-MSD in 2013 following positions at Astellas (Europe) in Business and Commercial Development P
O
and several years at Deloitte Corporate Finance where he headed up the Life Science Advisory practice assisting clients across R
T
the life science sector in a wide range of transactional activities (M&A, divestments, partnering, valuation, fund-raising). Prior IN
G
to Deloitte, Chris was at GlaxoSmithKline where he held roles of increasing responsibility in Business Development, Corporate O
Ventures and R&D. R
G
A
Chris holds a PhD in Biochemistry and an MBA in Finance. N
IS
A
T
IO
N
S
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
Chris Maggos, Alpine Institute for Drug Discovery
Chris has 20 years of experience in the life sciences industry covering business development, investor relations, communication,
investing and molecular neurobiology. Most recently, Chris has been working to establish the Alpine Institute for Drug t
Discovery, a social enterprise focused on translational drug discovery of novel immunotherapeutics via open innovation. b S
Prior to launching AIDD, Chris was a member of the executive management board at Addex Pharmaceuticals and held the ack PE
pPoresvitiioounssl yo hf eh ewaodr koefd i navse: sato jro urernlaatliiosnt sfo &r tchoem bmioutencichantoiolong y(2 t0ra0d7e- 2p0u1b0lic) aatniodn dBirioeCcteonr tuorf yb (u2s0in0e1s-s2 0d0ev7e);l oapnm inevnet s(t2o0r 1a0t -a2 0N1Y3C)-. :: nex AKER
based biotechnology hedge-fund (1997-2000), called Casdin Life Science Partners (later called Cooper Hill); and a molecular tu S
neurobiologist studying drug dependence at The Rockefeller University (1993-1997). He is co-author on 12 peer-reviewed
publications. Chris holds a BA from Yale University in English Literature (where he also completed pre-medical studies).
Christina Takke, Partner, Forbion Capital Partners
Christina holds a PhD in Developmental Biology, which she obtained under the supervision of Prof. Dr. Campos-Ortega at
the Institute of Development Biology of the University of Cologne. As an undergraduate Christina studied Molecular Biology/
Biochemistry at the Technical University of Darmstadt, Université de Bordeaux and at the Institut National de la Recherche
Agronomique (INRA) Montpellier. After her studies, she gained experience in working with biotech startup companies at
Bio-Gen-Tec-NRW in Cologne, Germany, a regional development organization for the biotechnology industry. She evaluated
business proposals and assisted the young biotech companies in the fundraising process. Christina joined the ABN AMRO P
R
Capital Life Sciences team as an analyst in 2000. Following this assignment she became Principal before being promoted to E
S
Partner. At Forbion Christina is responsible for scouting and analysis of new investment opportunities as well as general deal E
N
execution. Christina currently serves on the supervisory boards of Forbion’s portfolio companies Amakem NV, arGEN-X BV, T
and Pieris AG. In recent years she served on the board of Bioceros, and she was closely involved with GlycArt AG as a Board IN
G
Observer (sold to Roche in 2005). C
O
M
P
A
N
Corinne Savill, Head Business Development and Licensing, Novartis Pharma AG IE
S
Corinne has over 15 years of broad experience in both the pharmaceutical and biotech arena. In her current position, she has
responsibility for all Business development and partnering deals within Novartis.
After a Ph.D. in Immunology and a number of academic and pharmaceutical research positions, Corinne joined Imutran Ltd
a UK based Biotech as Director of Research. In 1996 Imutran was acquired by Novartis and Corinne made the COO. She
moved to Basel in 2001 as the CEO of the Novartis Bio Venture Fund, managing a CHF 100 million investment account
and establishing a new network for Novartis with venture capital companies in the US and Europe. Corinne then moved to
the Transplantation and Immunology Business Unit as Regional Manager, Western and Central Europe, where she was in
charge of 11 regions and countries. In 2005 Corinne moved to head up Global Search and Evaluation with Novartis Business
development where she was responsible for the identification and evaluation of potential license-in or M&A opportunities, S
U
growing the Novartis development pipeline and supporting the business goals of Novartis. In 2010 Corinne became Novartis’s P
P
Global Head of Pricing and Market Access responsible for the pricing and market access strategies for the entire portfolio of O
R
Novartis Pharma’s development and in Market products world-wide. T
IN
In June 2013 Corinne was appointed Head Business Development and Licensing Novartis Pharma AG. G
O
R
G
A
N
David Pinniger, Fund Manager, Polar Capital IS
A
David joined Polar Capital in August 2013 as a fund manager within the healthcare team. He has over 12 years’ investment TIO
experience in the healthcare sector. Prior to joining Polar Capital, David was a portfolio manager of the International N
S
Biotechnology Trust at SV Life Sciences. He also previously spent three years working at venture capital firm Abingworth as
an analyst managing biotechnology investments held across the firm’s venture and specialist funds, and four years at Morgan
Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. He is a CFA Charterholder.
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
David Urech, Co-CEO, CSO, Numab
David studied Molecular Biology and Neurosciences at the University of Zurich, where he received his master degree in
2000. He then joined Prof. Howard Riezman at the Biocenter of the University of Basel where he completed his Ph.D. in t
Biochemistry in 2004. As a Senior Scientist at Esbatech, David led the antibody discovery group and became Head of bac SP
Research & Development and member of the Senior Management in 2007. In this position he was responsible for the k E
dtreafinnsiftoiormn eodf athne i nsitciaiellnyt 5ifi-cp esotrpaltee dgiys, ceovvaelruya tteioanm o inf tdor aung intaterggeratst eadn Rde stheea rpcohs &it iDoneivneglo opfm Eesnbt autneict hc’osn psliasttifnogrm o f t3e0ch enmolpolgoyy.e eHse. :: nex AKER
This unit covered activities from technology development through antibody discovery and preclinical development. During tu S
his time at Esbatech, David developed a novel discovery platform, which reproducibly gives rise to highly potent and stable
antibody fragments. Further, his seeding scientific work on the pharmacokinetic properties of antibody fragments enabled the
development of Esbatechs TNF-inhibitory scFv that became the first antibody fragment to be successfully applied topically
by eye drops in a clinical setting. The technologies and products developed by David and his team turned out to be the
value driving factor for Esbatech’s acquisition by Alcon in September 2009. Most recently ESBA1008, an antibody fragment
developed by David’s group entered a clinical phase 2 trial. David is an inventor of over a dozen patent priority applications
and his scientific work has been published in numerous peer-reviewed journals.
Deborah Harland, VP & President, SR One
Deborah joined SR One in 2005 to establish the firm’s European investment office. She brings to SR One extensive operational, P
R
drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and E
S
business development during her more than 20 year tenure in the pharmaceutical industry. Deborah is currently a member E
N
of the Board of Directors of Mission Therapeutics Limited, Protaffin AG, Bicycle Therapeutics Limited, Syntaxin Limited, and T
f-star GmbH. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, IN
G
2007) and Pharmakodex Limited (sold to Orexo) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and C
O
7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from M
the University of London, and her MBA from Henley Management College. PA
N
IE
S
Dirk Beher, Chief Scientific Officer, Asceneuron SA
Dirk is a founder of Asceneuron SA and joined the company as Chief Scientific Officer at its inception. He led the spin-off
proposal for Merck Serono’s Alzheimer’s disease portfolio and successfully raised EUR 5M seed funding which materialized in
the creation of Asceneuron SA in October 2012. Dirk has more than 21 years of experience in the field of Alzheimer’s disease
and spent over 15 years in pharmaceutical drug discovery. Prior to Asceneuron he has held various positions with increasing
responsibility at major pharmaceutical and biopharmaceutical companies in worldwide geographical locations.
Previously, Dirk was the director of the Alzheimer’s and Parkinson’s Neurobiology Unit at Merck Serono in Geneva, Switzerland.
He was responsible for the strategic build-up of Alzheimer’s disease as a new indication and implemented the project portfolio SU
which represents Asceneuron’s pipeline. PP
O
Prior to Merck Serono Dirk worked in the Neuroscience Department at Amgen Inc. in Thousand Oaks, California where he R
T
managed the in vitro pharmacology team and oversaw a diverse CNS portfolio as management team member. Dirk started IN
his career in pharmaceutical drug discovery by joining Merck Sharp & Dohme (Merck & Co.) in Harlow, United Kingdom in G
O
1998. During that time he made key contributions to the clinical γ secretase inhibitor MK-0752 and was finally responsible R
G
for all γ secretase programs. A
N
Dirk holds a Ph.D. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Germany. He is an inventor IS
A
of seven patents and currently authors 47 peer-reviewed publications and reviews. T
IO
N
S
O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
Douglas M. Fambrough, CEO, Dicerna Pharmaceuticals, Inc.
Douglas is a co-founder of Dicerna Pharmaceuticals and joined the company as CEO in May 2010. Prior to joining Dicerna,
Dr. Fambrough spent over a decade as a biotechnology venture capitalist with Oxford Bioscience Partners, one of Dicerna’s t
investors. At Oxford, he specialized in financing innovative life science technology companies such as the first generation b S
RNA interference company, Sirna Therapeutics (acquired by Merck). Among his other investments are high-throughput DNA ack PE
sReibq-uXe nPchinagrm paiocneeuetirc Saolsl,e xaa (daecvqeuloirpeedr boyf I llaunmtiibniao)t;i cXse nacgoari,n wsth imchu eltni-gdirnuege rrse asinsttiabnotd yp Facth doogmenasin; sa tnod e nShoalsntcicee d Nruegu prorsocpieernticeess; :: nex AKER
(acquired by US WorldMeds). Prior to Oxford, Dr. Fambrough was a genomic scientist at the Whitehead/MIT Center for tu S
Genome Research (now known as the Broad Institute). Dr. Fambrough graduated from Cornell University and holds a Ph.D. in
genetics from the University of California, Berkeley.
Dr Edward D. Blair, Managing Director, Integrated Medicines Ltd
Dr Edward D. Blair is Managing Director of Integrated Medicines Ltd (IML), a company he formed in 2003 to enable
personalised medicine by combining diagnostic-type testing with new and existing medicines. He is also Chief Executive of
Integrated Magnetic Systems Ltd (IMSL), a non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, and
a visiting scholar to the Cambridge University Masters in Bioscience Enterprise programme. He also lectures on personalised
medicines and offers occasional bespoke courses based on his best-selling books.
Eddie has published more than 40 primary, peer-reviewed papers, including a series on companion diagnostic valuation, and P
R
is editor of two personalised medicine journals. Finally, he is named inventor on at least one dozen patents, including tuneable E
S
magnetic proteins, the technology being exploited by IMSL. EN
T
IN
G
Elena Startseva, Head of Business Development, OCT Clinical Trials CO
M
As a Head of Business Development, Elena is responsible for new business opportunities assessment and management; she P
A
supervises OCT’s advertising, client relations and budget negotiations. She manages development of OCT general capability N
IE
presentations as well as study specific presentations to clients from all over the world. S
Elena has started working in the Pharmaceutical/CRO industry in 2005 as a CRA and has a deep knowledge and expertise
in the field of clinical research.
Prior to joining the OCT team, Elena worked for Quintiles GesmbH as a Clinical Study Manager. After several years of
experience as a Senior Project Manager at OCT, Elena has been appointed to lead the Business Development team.
Elena holds Doctor of Medicine degree from the St. Petersburg Peadiatric Medical Academy, she completed residencies in
forensic and general pathology, and an MBA degree in International Business from Stockholm’s University.
S
U
Eric Halioua, MBA, Co-Founder and CEO, Promethera Biosciences P
P
O
Eric Halioua is the CEO and co-founder of the Belgian Biotechnology company Promethera Biosciences. Promethera® R
T
Biosciences’ mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative IN
way using stem cell from healthy human livers. He is as well Board members the biotechnology company Bioxodes, the G O
European Biopharmaceutical Enterprises (EBE) and of the Belgian Walloon region Biocluster (BioWin). R
G
Eric is co-founder of two biotechnology companies called Myosix and Murigenetics. Myosix is a tissue engineering company A
N
specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been sold to IS
A
Genzyme mid-2002. Murigenetics is a Biotechnology company developing therapies for genetic disorders. T
IO
Eric was also a Board Member of a French public biotechnology company called Vivalis, which specializes in the production N
S
of avian stem cells lines for the production of vaccines and recombinant proteins.
Eric was as well principal of the international life sciences practice of Arthur D. Little based in Paris and Boston during
11 years. He has led work in the areas of strategy, M&A and technology & innovation management for biotechnology and
pharmaceutical companies. Eric also worked as a strategic marketing manager for the “Centre Européen de Bioprospective”
and as project leader in the corporate R&D centre of Zeneca in UK.
Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business
school (Paris, France), with an advanced degree from the Health Care ESSEC chair. O
R
G
A
N
IS
E
R
S
W
E
L
C
O
M
E
Speakers
Eric Massou, CFO, Poxel Pharmaceuticals
Eric Massou has 19 years’ experience as an external auditor at Mazars and Ernst & Young, where he was mainly in charge
of industrial groups such as Becton Dickinson, Black & Decker, Brenntag or Candia. Eric acquired experience as a financial t
controller and group CFO at Veriplast Packaging, a plastic packaging company operating in 7 European countries. There, he b S
was involved in all recurrent financial aspects and monitored two major vendor due diligence projects to welcome Charterhouse ack PE
ienx t2e0rn0a4l satnadk eShUoNld ienr s2, 0a0n7d ahse nraeiwse sdh aarlle nheocldeesrssa. rIyn naedwd itmioonn, iEesri cto w sausp opno rtth beu dseinael stse agmro wfotrh a alln Md &finAa anccteiv intieews ainnddu sintr ciahl acragpee oxf. :: nex AKER
Eric received a Master in Finance at EM Strasbourg, the BESS program of Trinity College Dublin (Ireland) as well as the French tu S
CPA. Eric joined POXEL in January 2011.
Esteban Pombo-Villar, Chief Operations Officer, Oxford BioTherapeutics
Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20
years, the last 12 years of which he focused on all aspects of creating and managing alliances. Most recently he was Head of
Alliance Management at the Novartis Institute for Biomedical Research (NIBR), responsible for alliances up to proof-of-concept
in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz
Neuroscience Research in Basel in 1988. At Sandoz he worked on drug discovery projects as well as leading collaborative
projects investigating the potential of emerging technologies. Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry.
P
R
E
S
Dr Fintan Walton, Chief Executive Officer, PharmaVentures Ltd E
N
T
Dr Walton is the Founder and CEO of PharmaVentures. He was educated at the University of Michigan (US) and Trinity College IN
G
(Dublin, Ireland), and subsequently he gained broad commercial experience in biotechnology in management positions at Bass C
and Celltech plc (1982-1992). As an entrepreneur, Dr Walton co-founded CONNECT Pharma in 1992, a company focused on O
M
assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic alliances, P
A
Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures. His company has worked N
with blue chip clients on a global basis, delivering more than 600 assignments for companies in 37 countries. Clients have IE
S
included major pharmaceutical and biotechnology companies as well as diversified chemical corporations, medical device,
generic and OTC companies. His clients have also included major banks, investment/merchant banks, and private equity and
venture capital groups.
Although Fintan’s main focus is his role as Chief Executive Officer of PharmaVentures, he actively participates in many
consultancy assignments.
Dr Frank Grams, VP, Head of R&D Alliance Management & Transactions, Sanofi
S
Frank joined Sanofi in September 2011 as VP, Head R&D Alliance Management & Contracting. In this function he is leading UP
the early stage technology contracting activities and the R&D Alliance Management organization up to POC. PO
R
Before coming to Sanofi he has been working for Roche as Executive Director, Roche Partnering Asia, and as such has T
IN
been instrumental in setting up the Roche Pharma Partnering office in Shanghai starting in 2008. The office has been G
strengthening Roche’s presence in the region from China to Australia. O
R
Prior to taking up this post, Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic and life- G
A
cycle management activities related to drug delivery partnering. Frank was a Global Alliance Director from 2002, managing N
IS
pivotal research alliances such as Chugai, Evotec, SGX, Syrrx and Biotie. He has been involved in more than 100 transactions A
T
including product and technology deals, in- and out-licensing opportunities and also an acquisition. He is also one of the IO
initiators of the Greater China Life Sciences Business Plan Competition SEED (www.seedcompetition.com). N
S
Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, having previously worked
in various research functions in Roche and at Boehringer Mannheim GmbH.
Frank has a degree in chemistry from the University of Heidelberg and received his Ph.D. with summa cum laude from the
Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at
Martinsried, Germany).
O
R
G
A
N
IS
E
R
S